A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

The travel writer and host of 'Rick Steves Europe' shares an update after prostate cancer diagnosis to encourage men to 'say ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.